Education
About Us
Working with TipRanks
Follow Us
Bio-Techne (TECH)
NASDAQ:TECH
TECH Stock Chart & Stats
$58.18
-$0.13(-0.17%)
At close: 4:00 PM EST
$58.18
-$0.13(-0.17%)
Day’s Range― - ―
52-Week Range$46.01 - $79.28
Previous CloseN/A
Volume102.39K
Average Volume (3M)2.30M
Market Cap
$9.51B
Enterprise Value$8.95B
Total Cash (Recent Filing)$144.96M
Total Debt (Recent Filing)$380.70M
Price to Earnings (P/E)133.0
Beta0.91
Next Earnings
Feb 03, 2026EPS Estimate
0.44Last Dividend Ex-Date
Aug 18, 2025Dividend Yield0.53%
Share Statistics
EPS (TTM)0.42
Shares Outstanding155,693,440
10 Day Avg. Volume1,892,399
30 Day Avg. Volume2,303,988
Financial Highlights & Ratios
PEG Ratio-1.97
Price to Book (P/B)4.22
Price to Sales (P/S)6.64
P/FCF Ratio31.59
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue7.35
Enterprise Value/Gross Profit11.25
Enterprise Value/Ebitda45.45
Forecast
1Y Price Target
$68.38Price Target Upside17.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Growth OutlookManagement is confident that the growth outlook remains achievable with expected margin expansion.
Macro EnvironmentTechne should be among the most sensitive to the improving macro picture for tools, particularly relative to companies with greater bioprocessing exposure.
ValuationShares trade at a relatively low valuation compared to both the peer set and Techne's historical average.
Bears Say
Biotech Funding ChallengesShares traded down due to macro headwinds such as NIH, pharma tariffs, and biotech funding challenges.
Organic Growth ProjectionsManagement expects organic growth to be in the low single digits due to macro uncertainties.
Policy UncertaintiesThere is uncertainty due to policy issues such as NIH funding, pharma tariffs, and most-favored nation pricing, affecting short-term growth projections.
Bio-Techne News
TECH FAQ
What was Bio-Techne’s price range in the past 12 months?
Bio-Techne lowest stock price was $46.01 and its highest was $79.28 in the past 12 months.
What is Bio-Techne’s market cap?
Bio-Techne’s market cap is $9.51B.
When is Bio-Techne’s upcoming earnings report date?
Bio-Techne’s upcoming earnings report date is Feb 03, 2026 which is in 88 days.
How were Bio-Techne’s earnings last quarter?
Bio-Techne released its earnings results on Nov 05, 2025. The company reported $0.42 earnings per share for the quarter, missing the consensus estimate of $0.421 by -$0.001.
Is Bio-Techne overvalued?
According to Wall Street analysts Bio-Techne’s price is currently Undervalued.
Does Bio-Techne pay dividends?
Bio-Techne pays a Quarterly dividend of $0.08 which represents an annual dividend yield of 0.53%. See more information on Bio-Techne dividends here
What is Bio-Techne’s EPS estimate?
Bio-Techne’s EPS estimate is 0.44.
How many shares outstanding does Bio-Techne have?
Bio-Techne has 155,693,440 shares outstanding.
What happened to Bio-Techne’s price movement after its last earnings report?
Bio-Techne reported an EPS of $0.42 in its last earnings report, missing expectations of $0.421. Following the earnings report the stock price went down -1.899%.
Which hedge fund is a major shareholder of Bio-Techne?
Currently, no hedge funds are holding shares in TECH
Bio-Techne Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$68.38 (17.53% Upside)
$68.38 (17.53% Upside)
Blogger Sentiment
Bullish
TECH Sentiment 83%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 687.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.4%
Last 30 Days ▲ 35.7%
Last 30 Days ▲ 35.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.36%
12-Months-Change
Fundamentals
Return on Equity
3.80%
Trailing 12-Months
Asset Growth
-9.08%
Trailing 12-Months
Company Description
Bio-Techne
Bio-Techne Corporation (TECH) is a leading global supplier of life science reagents and instruments, primarily serving the pharmaceutical and biotechnology sectors, as well as academic research institutions. The company operates through two main segments: the Protein Platforms segment, which includes a wide array of proteins, antibodies, and reagents used for research and diagnostic applications; and the Diagnostics segment, which offers a range of products for molecular diagnostics and protein analysis. Bio-Techne is known for its innovative solutions that support the development of new therapeutics and diagnostic tests.
TECH Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a mixed performance for Bio-Techne. While there are significant challenges in biotech funding and revenue declines in specific segments, there are positive developments in large pharma growth, geographic expansion in China, and margin improvements. The company also made notable progress in sustainability and some product lines, but faces hurdles in cell therapy and biotech funding.View all TECH earnings summariesTECH Net revenue Breakdown
71.35% Protein Sciences
28.39% Diagnostics and Genomics
0.34% Other
TECH Stock 12 Month Forecast
Average Price Target
$68.38
▲(17.53% Upside)
Technical Analysis
Corcept Therapeutics
―
Halozyme
―
Jazz Pharmaceuticals
―
Rhythm Pharmaceuticals
―
Roivant Sciences
―
Ownership Overview
0.26% Insiders
39.83% Mutual Funds
2.78% Other Institutional Investors
32.35% Public Companies and
Individual Investors